Bioengineered AAV vectors with increased skeletal muscle potency and specificity for systemic gene therapy of myotubular myopathy - Archive ouverte HAL Accéder directement au contenu
Poster De Conférence Année : 2021

Bioengineered AAV vectors with increased skeletal muscle potency and specificity for systemic gene therapy of myotubular myopathy

Elandari Jihad
  • Fonction : Auteur
Louise Mangin
Weinmann Jonas
  • Fonction : Auteur
Esther Attebi
  • Fonction : Auteur
Emanuele Bourges
  • Fonction : Auteur
Nicolas Guerchet
  • Fonction : Auteur
  • PersonId : 1126617
Fakhiri Julia
  • Fonction : Auteur
Krämer Chiara
  • Fonction : Auteur
Wiedtke Ellen
  • Fonction : Auteur
Hebben Matthias
  • Fonction : Auteur
Grimm Dirk
  • Fonction : Auteur
Ana Buj-Bello

Résumé

X-linked myotubular myopathy (XLMTM) is a severe congenital disorder characterized by generalized hypotonia and muscle weakness, frequently associated with fatal respiratory failure. The disease is caused by loss-of-function mutations in the MTM1 gene, which encodes myotubularin. We demonstrated the therapeutic efficacy of intravenous delivery of serotype 8 adeno-associated viral vectors (AAV8) expressing myotubularin in murine and canine animal models of the disease, representing the basis of an ongoing clinical trial in patients. In the present study, we generated and assessed the efficacy of two novel AAV vectors, AAVS1P1 and AAVS10P1, which are composed of hybrid capsids and a small VP1 peptide insertion, in Mtm1-KO mice. Intravenous administration of either AAVS1P1- or AAVS10P1-MTM1 vectors prolonged the lifespan of mutant animals and resulted in a higher increase in muscle mass, strength, and transgene expression compared to AAV8-MTM1 at the same dose, and in liver transduction detargeting. Our findings indicate that these novel vectors are more potent than AAV8 in rescuing the phenotype of myotubular myopathy mice, and hold great potential for gene therapy of other inherited disorders affecting skeletal muscles.
Fichier non déposé

Dates et versions

hal-04488882 , version 1 (04-03-2024)

Identifiants

  • HAL Id : hal-04488882 , version 1

Citer

Edith Renaud-Gabardos, Elandari Jihad, Louise Mangin, Weinmann Jonas, Esther Attebi, et al.. Bioengineered AAV vectors with increased skeletal muscle potency and specificity for systemic gene therapy of myotubular myopathy. ESGCT, 2021, PARIS, France. ⟨hal-04488882⟩
11 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More